/
AIM ImmunoTech Inc. and its subsidiaries are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders for which there are inadequate or unmet therapies. We have established a strong foundation of laboratory, pre-clinical and clinical data with r…
The business is unprofitable at the operating level (-13254.55% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 48.2% YoY. Margins deteriorated 1624.0pp alongside, both lines moving the wrong way.
Negative free cash flow of -$11M. The business is consuming cash, not generating it. Operating margin contracted 1624.0pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$94K
▼ -48.2% YoY
Net Income (TTM)
-$13M
▲ +19.4% YoY
Op. Margin
-10926.60%
▼ -1624.0pp YoY
ROIC
-104.09%
▲ +52.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +26.5% YoY
Op. Cash Flow (TTM)
-$11M
▲ +26.4% YoY
Net Debt
$3M
Cash & Equiv.
$6M
5Y CAGR: -11.6%
Continue Research